MDT

84.7

+0.83%↑

VEEV

231.57

+2.63%↑

A

107.51

+0.6%↑

WBA

10.91

-0.46%↓

CHE

575.22

+1.75%↑

MDT

84.7

+0.83%↑

VEEV

231.57

+2.63%↑

A

107.51

+0.6%↑

WBA

10.91

-0.46%↓

CHE

575.22

+1.75%↑

MDT

84.7

+0.83%↑

VEEV

231.57

+2.63%↑

A

107.51

+0.6%↑

WBA

10.91

-0.46%↓

CHE

575.22

+1.75%↑

MDT

84.7

+0.83%↑

VEEV

231.57

+2.63%↑

A

107.51

+0.6%↑

WBA

10.91

-0.46%↓

CHE

575.22

+1.75%↑

MDT

84.7

+0.83%↑

VEEV

231.57

+2.63%↑

A

107.51

+0.6%↑

WBA

10.91

-0.46%↓

CHE

575.22

+1.75%↑

Search

Heron Therapeutics Inc

Open

BrancheGesundheitswesen

2.39 6.22

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

2.23

Max

2.4

Schlüsselkennzahlen

By Trading Economics

Einkommen

8.5M

3.7M

Verkäufe

-1.5M

41M

EPS

0.02

Gewinnspanne

8.982

Angestellte

122

EBITDA

13M

8.7M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+182.61% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

6. Mai 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

25M

294M

Vorheriger Eröffnungskurs

-3.83

Vorheriger Schlusskurs

2.39

Technischer Score

By Trading Central

Vertrauen

Strong Bullish Evidence

Heron Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

28. Apr. 2025, 23:27 UTC

Top News

Woodside Energy Approves $17.5 Billion Louisiana LNG Development -- 2nd Update

28. Apr. 2025, 23:07 UTC

Top News

Woodside Energy Approves $17.5 Billion Louisiana LNG Development -- Update

28. Apr. 2025, 23:03 UTC

Ergebnisse

Waste Management 1Q Profit Falls, Revenue Misses Estimates

28. Apr. 2025, 23:47 UTC

Market Talk

Gold Edges Lower as Traders Assess Mixed Signals From Treasury Secretary Bessent -- Market Talk

28. Apr. 2025, 23:17 UTC

Ergebnisse

Jiangxi Copper 1Q Rev CNY111.61B Vs. CNY122.52B >0358.HK

28. Apr. 2025, 23:17 UTC

Ergebnisse

Jiangxi Copper 1Q Net CNY1.95B Vs. Net CNY1.71B >0358.HK

28. Apr. 2025, 23:13 UTC

Ergebnisse

China Merchants Securities: Higher Interest Income, Fee Income Also Aided 1Q Results>600999.SH

28. Apr. 2025, 23:13 UTC

Ergebnisse

China Merchants Securities 1Q Rev CNY4.71B Vs. CNY4.30B >600999.SH

28. Apr. 2025, 23:13 UTC

Ergebnisse

China Merchants Securities: Gains From Investments in Financial Instruments Supported Results >600999.SH

28. Apr. 2025, 23:13 UTC

Ergebnisse

China Merchants Securities 1Q Net CNY2.31B Vs. Net CNY2.16B >600999.SH

28. Apr. 2025, 23:08 UTC

Ergebnisse

China Longyuan Power: 1Q Power Generation Declined 4.42% on Year>0916.HK

28. Apr. 2025, 23:08 UTC

Ergebnisse

China Longyuan Power 1H Rev CNY8.14B Vs. CNY8.07B >0916.HK

28. Apr. 2025, 23:08 UTC

Ergebnisse

China Longyuan Power 1H Net CNY1.98B Vs. Net CNY2.53B >0916.HK

28. Apr. 2025, 23:04 UTC

Ergebnisse

Huaneng Power: 1Q Net Was Mainly Driven By Decline in Domestic Fuel Costs >0902.HK

28. Apr. 2025, 23:04 UTC

Ergebnisse

Huaneng Power: Decrease in Electricity Tariffs Weighed on Rev >0902.HK

28. Apr. 2025, 23:04 UTC

Ergebnisse

Huaneng Power 1Q Rev CNY60.33B ; Down 7.7% on Year>0902.HK

28. Apr. 2025, 23:04 UTC

Ergebnisse

Huaneng Power 1Q Net CNY4.97B; up 8.2% on Year >0902.HK

28. Apr. 2025, 23:00 UTC

Ergebnisse

Jiangsu Expressway 1Q Rev CNY4.78B Vs. CNY3.47B >0177.HK

28. Apr. 2025, 23:00 UTC

Ergebnisse

Jiangsu Expressway: 1Q Rev Rose Due to Increase in Road Construction Projects >0177.HK

28. Apr. 2025, 23:00 UTC

Ergebnisse

Jiangsu Expressway: Decline in Investment Income, Fall in Revenue Post Asset Disposal Weighed on 1Q Net >0177.HK

28. Apr. 2025, 23:00 UTC

Ergebnisse

Jiangsu Expressway 1Q Net CNY1.21B Vs. Net CNY1.25B >0177.HK

28. Apr. 2025, 22:57 UTC

Top News

Trump Signs Order Requiring Nationwide List of Sanctuary Cities and States -- 8th Update

28. Apr. 2025, 22:55 UTC

Ergebnisse

Tsingtao Brewery: Higher Sales Volumes of Beer Supported Results >0168.HK

28. Apr. 2025, 22:55 UTC

Ergebnisse

Tsingtao Brewery 1Q Net CNY1.71B Vs. Net CNY1.60B >0168.HK

28. Apr. 2025, 22:55 UTC

Ergebnisse

Tsingtao Brewery 1Q Rev CNY10.45B Vs. CNY10.15B >0168.HK

28. Apr. 2025, 22:52 UTC

Ergebnisse

S.F. Holding: Results Supported by Higher Contributions From Logistics Business >002352.SZ

28. Apr. 2025, 22:52 UTC

Ergebnisse

S.F. Holding 1Q Net CNY2.23B Vs. Net CNY1.91B >002352.SZ

28. Apr. 2025, 22:52 UTC

Ergebnisse

S.F. Holding: Cost Controls Also aided 1Q Results >002352.SZ

28. Apr. 2025, 22:52 UTC

Ergebnisse

S.F. Holding 1Q Rev CNY69.85B Vs. CNY65.34B >002352.SZ

28. Apr. 2025, 22:46 UTC

Ergebnisse

Shandong Gold Mining: Increase in Selling Price of Gold Supported Results>600547.SH

Peer-Vergleich

Kursveränderung

Heron Therapeutics Inc Prognose

Kursziel

By TipRanks

182.61% Vorteil

12-Monats-Prognose

Durchschnitt 6.5 USD  182.61%

Hoch 9 USD

Tief 4 USD

Basierend auf 2 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Heron Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

2 ratings

2

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

2.2 / 2.38Unterstützung & Widerstand

Kurzfristig

Strong Bullish Evidence

Mittelfristig

Very Strong Bullish Evidence

Langfristig

Bullish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Heron Therapeutics Inc

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.